ArticleInternational journal of molecular medicine2019
Ubiquitin‑proteasomes are the dominant mediators of the regulatory effect of microRNA‑1 on cardiac remodeling after myocardial infarction.
Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- The role of different types of programmed cell death in myocardial fibrosis: from mechanisms to therapeutics.Frontiers in cardiovascular medicine · 2026Review
- Extracellular vesicles-delivered circDB promotes ischemic muscle repair through the miR-34a/USP7/Notch1 signaling pathway.Regenerative therapy · 2025Article
- Unveiling the role of PSMA5 in glioma progression and prognosis.Discover oncology · 2024Article
- Crosstalk of ubiquitin system and non-coding RNA in fibrosis.International journal of biological sciences · 2024Review
- Crosstalk between ubiquitin ligases and ncRNAs drives cardiovascular disease progression.Frontiers in immunology · 2024Review
- Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances.Journal of translational medicine · 2023Review
- Noncoding RNAs and Cardiac Fibrosis.Reviews in cardiovascular medicine · 2023Review
- Acacetin alleviates myocardial ischaemia/reperfusion injury by inhibiting oxidative stress and apoptosis via the Nrf-2/HO-1 pathway.Pharmaceutical biology · 2022Article
- Cerebral derailment after myocardial infarct: mechanisms and effects of the signaling from the ischemic heart to brain.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Plasma hsa-mir-19b is a potential LevoDopa therapy marker.Journal of cellular and molecular medicine · 2021Article
- Inhibiting miR‑1 attenuates pulmonary arterial hypertension in rats.Molecular medicine reports · 2021Article
- YQHX Alleviates H/R-Induced Cardiomyocyte Apoptosis by Downregulating miR-1.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Effect of Danqi Buxin Decoction on Chronic Function Indexes and Life Quality in Patients with Chronic Heart Failure of Yang Deficiency Type.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Different Expressions of Pericardial Fluid MicroRNAs in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy and Ischemic Heart Disease Undergoing Ventricular Tachycardia Ablation.Frontiers in cardiovascular medicine · 2021Article
- Endoplasmic reticulum stress serves an important role in cardiac ischemia/reperfusion injury (Review).Experimental and therapeutic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with ischemic hearts who have refused coronary vascular reconstruction may exhibit dynamic myocardial remodeling and cardiac dysfunction. In the present study, the role of miRNA‑1 and its association with the ubiquitin‑proteasome system (UPS) in regulating myocardial remodeling was investigated. A myocardial infarction (MI) model was constructed and the hearts were treated with miRNA‑1 antagomir, miRNA‑1 lentiviral vectors and the UPS proteasome blocker bortezomib. The expression levels of miRNA‑1 were evaluated using reverse transcription PCR and the abundance of the ubiquitin‑proteasome protein and caspase‑3 were evaluated via western blot analysis. Furthermore, the collagen volume fraction was calculated using Masson's trichrome staining, and the apoptosis index was detected via terminal deoxynucleotidyl transferase dUTP‑biotin nick end labeling staining. Transforming growth factor (TGF)‑β expression was assessed via immunohistochemical staining. Echocardiographic characteristics and myocardial infarct size were analyzed. miRNA‑1 expression levels were found to be increased following MI. miRNA‑1 antagomir administration clearly inhibited miRNA‑1 expression, whereas the miRNA‑1 lentiviral vector exerted the opposite effect. The levels of 19s proteasome, 20S proteasome and ubiquitin ligase E3 were decreased in the miRNA‑1 antagomir group, but were significantly increased in the miRNA‑1 lentiviral group; however, only 20S proteasome expression was decreased in the bortezomib group. Collagen hyperplasia and TGF‑β expression were decreased in both the miRNA‑1 antagomir and bortezomib groups, although the effects of the miRNA‑1 antagomir were more noticeable. The miRNA‑1 antagomir and the UPS proteasome blocker both alleviated the ultrastructural impairments, demonstrated by a decreased left ventricular (LV) end‑diastolic diameter and LV mass, but the miRNA‑1 antagomir was also able to increase LV ejection fraction and LV fractional shortening. miRNA‑1 regulated UPS‑associated mRNA expression and affected the majority of the UPS components in the myocardium, thereby leading to increased myocardial cell apoptosis, myocardial fibrosis and remodeling. The miRNA‑1 antagomir exerted a more prominent cardioprotective effect compared with the UPS proteasome blocker bortezomib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.